What is Skye Bioscience Price-to-Operating-Cash-Flow?
As of today (2024-05-21), Skye Bioscience's share price is $11.98.
Skye Bioscience's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.51. Hence, Skye Bioscience's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Skye Bioscience's Price-to-Operating-Cash-Flow or its related term are showing as below:
Skye Bioscience's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-0.17.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.51.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 32.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.30% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 11.30% per year.
During the past 12 years, Skye Bioscience's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.10% per year. The lowest was -384.10% per year. And the median was 26.95% per year.
Skye Bioscience Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Skye Bioscience's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience Price-to-Operating-Cash-Flow Chart
|
Skye Bioscience Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Skye Bioscience Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Skye Bioscience's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Skye Bioscience's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skye Bioscience's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Skye Bioscience's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's Price-to-Operating-Cash-Flow falls into.
Skye Bioscience Price-to-Operating-Cash-Flow Calculation
Skye Bioscience's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 11.98 | / | -1.507 |
| = | |
Skye Bioscience's Share Price of today is $11.98.
Skye Bioscience's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Skye Bioscience (Skye Bioscience) Business Description
Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.
Executives
| Punit Dhillon |
director |
5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
| John D Diekman |
10 percent owner |
C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Partners Vii, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Paul A. Grayson |
director |
10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
| 5am Ventures Vii, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Kush Parmar |
10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Partners Ii, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Co-investors Ii Lp |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Versant Ventures Iii, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Scott M Rocklage |
10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Andrew J. Schwab |
director, 10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Versant Side Fund Iii, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| 5am Ventures Ii Lp |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Versant Venture Capital Iii, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Deborah H. Charych |
director |
1001 17TH ST, SAN FRANCISCO CA 94107 |
Skye Bioscience (Skye Bioscience) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SKYE has been successfully added to your